Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567073 · ClinicalTrials.gov registry record
Pompe Pregnancy Sub-Registry
A clinical trial of Pompe Disease (Late-onset) and Glycogen Storage Disease Type II (GSD-II), sponsored by Genzyme, a Sanofi Company.
- Recruiting
- Registry status
- 20
- Enrollment target
- 20
- Study locations
NCT00567073: Recruiting study of Pompe Disease (Late-onset) and Glycogen Storage Disease Type II (GSD-II), sponsored by Genzyme, a Sanofi Company.
NCT00567073 is a study of Pompe Disease (Late-onset) and Glycogen Storage Disease Type II (GSD-II) that is actively recruiting participants, run by Genzyme, a Sanofi Company. The registered enrollment target is 20 participants, below the 45-participant average among 8 other Pompe Disease (Late-onset) trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567073, a study of Pompe Disease (Late-onset) and Glycogen Storage Disease Type II (GSD-II), is actively recruiting participants, sponsored by Genzyme, a Sanofi Company.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Pompe disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with alglucosidase alfa or avalglucosidase alfa.
Conditions Studied
Study Locations (20)
Other
- Investigational Site Number : 056001 - Ghent
- Investigational Site Number : 1910001 - Zagreb
- Investigational Site Number : 1910002 - Zagreb
- Investigational Site Number : 2030001 - Prague
- Investigational Site Number : 380008 - Brescia
- Investigational Site Number : 380006 - Cagliari
- Investigational Site Number : 380005 - Florence
- Investigational Site Number : 380004 - Genova
- Investigational Site Number : 380013 - Messina
- Investigational Site Number : 380007 - Milan
New York
- New York University School Of Medicine- Site Number : 840040 - New York
- Mt. Sinai School of Medicine- Site Number : 840005 - New York
Arizona
- Barrow Neurol Group- Site Number : 840087 - Phoenix
Georgia
- Emory University School Of Medicine- Site Number : 840060 - Atlanta
Indiana
- Indianapolis University School of Medicine- Site Number : 840027 - Indianapolis
Michigan
- Spectrum for Health- Site Number : 840019 - Grand Rapids
North Carolina
- Duke University Medical Center Genetics Dept- Site Number : 840037 - Durham
Ohio
- LSD Data Registry Site LLC- Site Number : 840094 - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-06-18 |
| Est. Completion | 2034-01-31 |
What NCT00567073 shows while recruiting
NCT00567073 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 45-participant average among 8 other Pompe Disease (Late-onset) trials with a reported enrollment target (56% lower).
The record links to 3 conditions, with Pompe Disease (Late-onset) appearing as the primary indexed condition, and to 0 interventions.
NCT00567073 names 20 study sites across 10 states, led by Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT00567073 about?
NCT00567073 is a clinical study titled "Pompe Pregnancy Sub-Registry". This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or av...
What is the current status of trial NCT00567073?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2007-06-18. Estimated completion is 2034-01-31.
What conditions does trial NCT00567073 study?
This clinical trial studies the following conditions: Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency.
Who is sponsoring clinical trial NCT00567073?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00567073 being conducted?
This trial has 20 study locations across Arizona, Georgia, Indiana, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pompe Disease (Late-onset)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00567073's enrollment target sits among peer trials
20 5th of 8 higher than 3 of 8 other Pompe Disease (Late-onset) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pompe Disease (Late-onset) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)
RECRUITING · Phase 1
-
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
ACTIVE NOT RECRUITING · Phase 3
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
ACTIVE NOT RECRUITING · Phase 1
-
Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
ACTIVE NOT RECRUITING
-
Gene Transfer Study in Patients With Late Onset Pompe Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI